Trial Profile
Value of Abciximab in Patients With AMI Undergoing PCI After High Dose Clopidogrel Pretreatment (BRAVE 3)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Oct 2022
Price :
$35
*
At a glance
- Drugs Abciximab (Primary) ; Clopidogrel
- Indications Cardiovascular disorders; Embolism and thrombosis; Myocardial infarction
- Focus Therapeutic Use
- Acronyms BRAVE-3
- 14 Apr 2009 Results published in Circulation.
- 31 Mar 2009 Results were presented at the 58th Annual Scientific Session of the American College of Cardiology (ACC-2009).
- 31 Mar 2008 Status changed from in progress to completed.